Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers

作者：Dena Marrinucci, Kelly Bethel, Anand Kolatkar, Madelyn Luttgen, Michael Malchiodi, Franziska Baehring, Katharina Voigt, Daniel C. Lazar, Jorgé Nieva, Lyudmila Bazhenova, Andrew H. Ko, W. Michael Korn, Ethan Schram, M. P. Coward, Xing Yang, Thomas J. Metzner, R Lamy, Meghana Honnatti, Craig Yoshioka, Joshua Kunken, Yelena Petrova, Devin Sok, David M. Nelson, Peter Kühn · 发表于：Physical Biology · 年份：2012 · DOI：10.1088/1478-3975/9/1/016003 · 被引用次数：305 · 研究领域：Cancer Cells and Metastasis、Cancer Genomics and Diagnostics、3D Printing in Biomedical Research

Hematologic spread of carcinoma results in incurable metastasis; yet, the basic characteristics and travel mechanisms of cancer cells in the bloodstream are unknown. We have established a fluid phase biopsy approach that identifies circulating tumor cells (CTCs) without using surface protein-based enrichment and presents them in sufficiently high definition (HD) to satisfy diagnostic pathology image quality requirements. This 'HD-CTC' assay finds >5 HD-CTCs mL(-1) of blood in 80% of patients with metastatic prostate cancer (n = 20), in 70% of patients with metastatic breast cancer (n = 30), in 50% of patients with metastatic pancreatic cancer (n = 18), and in 0% of normal controls (n = 15). Additionally, it finds HD-CTC clusters ranging from 2 HD-CTCs to greater than 30 HD-CTCs in the majority of these cancer patients. This initial validation of an enrichment-free assay demonstrates our ability to identify significant numbers of HD-CTCs in a majority of patients with prostate, breast and pancreatic cancers.